Articles From: Bio-Rad to Report Third-Quarter 2014 Financial Results Tuesday, November 4, 2014 to BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases


http://media.marketwire.com/attachments/201308/181926_BIO-RADLOGO.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1150372&ProfileId=051205&sourceType=1 HERCULES, CA --
Sign-up for Bio-Rad to Report Third-Quarter 2014 Financial Results Tuesday, November 4, 2014 investment picks
MINNEAPOLIS , Aug.
Sign-up for Bio-Techne Announces Appointment Of Brenda Furlow As General Counsel investment picks
MINNEAPOLIS , Aug.
Sign-up for Bio-Techne Announces ProteinSimple Acquisition Completion investment picks
MINNEAPOLIS , Aug.
Sign-up for Bio-Techne Declares Dividend investment picks
MINNEAPOLIS , Aug.
Sign-up for Bio-Techne Releases Fourth Quarter And Full Year 2014 Results investment picks
LAS VEGAS , Aug.
Sign-up for BioAdaptives Announces First Product to Market investment picks
MINNEAPOLIS, MN , Aug.
Sign-up for BioAmber Reports Second Quarter 2014 Financial Results investment picks
BioAmber Signs Exclusive Supply Agreement for Bio-Succinic Acid Canada NewsWire 5 year supply agreement is with Xuchuan Chemical, a global leader in polyester polyols BioAmber bio-succinic acid will initially be used to produce cast polyurethane elastomers (CPU). Other applications for BioAmber succinic acid include resins for shoe soles and synthetic leathers Xuchuan operates 4 production facilities in China , with a total capacity of 150,000 tons per year The market opportunity for bio-succinic acid at Xuchuan is several thousand tons per year MONTREAL , Oct.
Sign-up for BioAmber Signs Exclusive Supply Agreement for Bio-Succinic Acid investment picks
5 year supply agreement is with Xuchuan Chemical, a global leader in polyester polyols BioAmber bio-succinic acid will initially be used to produce cast polyurethane elastomers (CPU). Other applications for BioAmber succinic acid include resins for shoe soles and synthetic leathers Xuchuan operates 4 production facilities in China , with a total capacity of 150,000 tons per year The market opportunity for bio-succinic acid at Xuchuan is several thousand tons per year MONTREAL , Oct.
Sign-up for BioAmber Signs Exclusive Supply Agreement for Bio-Succinic Acid investment picks
BioAmber to Announce Third Quarter 2014 Financial Results on November 6, 2014 Canada NewsWire Minneapolis, MN , Oct.
Sign-up for BioAmber to Announce Third Quarter 2014 Financial Results on November 6, 2014 investment picks
Minneapolis, MN , Oct.
Sign-up for BioAmber to Announce Third Quarter 2014 Financial Results on November 6, 2014 investment picks
Interim Data on First 11 Patients in the Ongoing Phase 2/3 HOPEMD Study Suggest Cabaletta to be Safe and Well Tolerated with No Drug Related Adverse Events TEL AVIV, Israel, Sept.
Sign-up for BioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study in OPMD investment picks
TEL AVIV, Israel, Aug.
Sign-up for BioBlast Pharma Reports Second Quarter Financial Results investment picks
TEL AVIV, Israel, Sept.
Sign-up for BioBlast to Ring the NASDAQ Stock Market Opening Bell investment picks
SAN DIEGO and PRINCETON, N.J. and REHOVOT, Israel, Oct.
Sign-up for Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells investment picks
SAN DIEGO, Oct.
Sign-up for Biocept Expands Collaboration With MD Anderson Cancer Center investment picks
SAN DIEGO, Aug.
Sign-up for Biocept Provides Second Quarter Operational Update investment picks
SAN DIEGO, Sept.
Sign-up for Biocept Strengthens Its Circulating Tumor Cell IP Position in Europe investment picks
SAN DIEGO, Sept.
Sign-up for Biocept to Present at the 13th Annual BIO Investor Forum investment picks
SAN DIEGO, Sept.
Sign-up for Biocept to Present at Upcoming Investor Conferences investment picks
RESEARCH TRIANGLE PARK, N.C., Oct.
Sign-up for BioCryst Announces Late Breaker Presentation of OPuS-1 Phase 2 Trial Results at the 23rd EADV Congress investment picks
RESEARCH TRIANGLE PARK, N.C., Sept.
Sign-up for BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting investment picks
RESEARCH TRIANGLE PARK, N.C., Sept.
Sign-up for BioCryst Participates in World Health Organization Consultation on Potential Ebola Therapies investment picks
RESEARCH TRIANGLE PARK, N.C., Sept.
Sign-up for BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Bio-Rad to Report Third-Quarter 2014 Financial Results Tuesday, November 4, 2014 to BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices